About
Science
Our Science
CER Mechanism of Action
CER Technology Platform
Related Literature
Pipeline
Careers
Investors
Contact
Investors
Committee charters and governance documents
Committee Charter
Audit Committee Charter
› Download PDF
Committee Charter
Nominating and Corporate Governance Charter
› Download PDF
Committee Charter
Compensation Committee Charter
› Download PDF
Governance Document
Corporate Governance Guidelines
› Download PDF
Governance Document
Code of Conduct and Ethics
› Download PDF
SEC filings
Title
Form Type
Filing Date
Report Date
Accession Number
Link
View More
Data source CIK0001870404.json
Recent news and events
Mar 07, 2024
CERo Therapeutics, Inc. Announces Publication of Preclinical Research Supporting the Use of Its Clinical Candidate CER-1236 to Treat AML Patients
Feb 14, 2024
Phoenix Biotech Acquisition Corp. and Cero Therapeutics Holdings, Inc. Announce Close of Business Combination
Jun 05, 2023
CERo Therapeutics, Inc. and Phoenix Biotech Acquisition Corp. Announce Merger Agreement to Create Public Company Advancing the Development of Next Generation Engineered T Cell Therapeutics
May 15, 2023
Chimeric TIM-4 receptor-modified T cells targeting phosphatidylserine mediates both cytotoxic anti-tumor responses and phagocytic uptake of tumor-associated antigen for T cell cross presentation
May 02, 2022
CERo Therapeutics’ Multifunctional CER T Cells Synergize with Standard of Care Small Molecule Anti-Tumor Inhibitors Across Hematologic and Solid Tumor Models
Nov 12, 2021
CERo Therapeutics’ Novel Chimeric Engulfment Receptor T Cells Exhibit Multifunctional Properties and Enhanced Tumor Killing